Who is involved with the event presentations?
Kelvin Nanotechnology Ltd - Dr Brendan Casey
Kelvin Nanotechnology Ltd (KNT) provide nanofabrication solutions to industry and academia delivered through the state of the art James Watt Nanofabrication Centre. With the proliferation of nanotechnology into new application spaces, the company is constantly expanding and developing our industrially facing processes and technology from textiles to food from life sciences to engineering.
Pharmacells – Athol Haas CEO & Dr Neil Fell
Pharmacells has the exclusive rights to a patented method of harvesting and storing a special new type of adult, blood derived stem cell. Our business model consists of both consumer and commercial target markets with the creation of a private stem cell bank for the discerning individual; alongside supply of our cell line into commercial projects including research and Pharmaceutical R&D.
Stem cell research will lead to personalised treatments and therapies for everything from cancers to tissue repair and it is important that individuals take the time to bank their stem cells whilst healthy.
Pharmacells was first discussed in 2006 by Dr Neil Fell and together with Mr Athol Haas, they formed their business in 2008. They’re funded by both private investment monies and Public Sector funds. Dr Fell is a medical doctor with an intercalated research degree, qualified from the University of Aberdeen. Mr Haas brings extensive business experience having started, built and now sold out of a successful telecom provider. Together they have the medical knowledge and business acumen to take Pharmacells onto major successes.
Who are our Guest Commentators for the event?
Bill Matthews of M2M2 will comment on Kelvin Nanotechnology Ltd. Bill Matthews began his diverse career by rising through the ranks at Motorola, from engineer through marketing and operations to the position of Director of Strategy and Systems for a $1B automotive components business. Headhunted into the SME world, Bill spent an interesting 5 years riding boom and bust in VC-backed businesses, before developing a portfolio career. Today Bill is Chair of a NHS Board and a non-exec director on two NDPBs and one core Scottish Government department. He is the founder of M2M2, which combines a music management business with a home for his management consulting activity. Bill has first degrees in Electronics and Psychology and an MBA
Dr David C Bunton of Biopta will comment on Pharmacells. David is co-founder and CEO of Biopta. An expert in vascular pharmacology, David is a graduate from the University of Glasgow and has a PhD from Glasgow Caledonian University with numerous publications in respiratory and vascular pharmacology. David is a member of the British Pharmacological Society.